Climb Bio Inc (NASDAQ:CLYM) is one of the tiny stocks that are on fire right now. On April 7, Climb Bio received FDA Fast ...
A significantly greater percentage of patients achieved complete remission with obinutuzumab vs with tacrolimus at 104 weeks. Topline results were announced from a phase 3 trial evaluating ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
No therapies currently exist that can halt the progression of chronic kidney disease in children or restore the ability of kidney cells to filter blood. Recently, researchers at the GOFARR Laboratory ...
– MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years – – Up to 30% of people with membranous nephropathy progress ...
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN) There are currently no therapies ...
I am currently caring for a 74-year-old man with a 2-month history of progressive nephrotic syndrome and cholestatic jaundice. What are the most likely diagnoses to consider? This is a challenging ...
New research reveals that contrary to conventional belief, primary glomerular diseases are not necessarily benign for children and young adults. In fact, some subsets of children and young adults may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results